Xin Lang Cai Jing·2026-02-25 08:46Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration to conduct clinical trials for Rumaine® (Luwotamab tablets) in combination with Anlotinib for patients with KRAS-mutated advanced NSCLC [1] Group 1: Clinical Trial Approvals - The company plans to initiate Phase II clinical trials in China once conditions are met [1] - The drug has already been approved for two indications in China as of February 25, 2026, with two additional applications accepted for priority review [1] Group 2: Research and Development Investment - As of January 2026, the total R&D investment for this drug has reached approximately 668 million yuan [1] - There are currently two clinical trials in Phase III and Phase II stages for the drug [1]